-
1
-
-
0027129391
-
Metabolic disturbances and wasting in the acquired immunodeficiency syndrome
-
Grunfeld C, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med. 1992 ; 327: 329-337.
-
(1992)
N Engl J Med
, vol.327
, pp. 329-337
-
-
Grunfeld, C.1
Feingold, K.R.2
-
2
-
-
0033583977
-
Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
-
DOI 10.1016/S0140-6736(98)08468-2
-
Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, (Pubitemid 29278477)
-
(1999)
Lancet
, vol.353
, Issue.9170
, pp. 2093-2099
-
-
Carr, A.1
Samaras, K.2
Thorisdottir, A.3
Kaufmann, G.R.4
Chisholm, D.J.5
Cooper, D.A.6
-
3
-
-
19944431796
-
Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine
-
DOI 10.1097/01.qai.0000143599.64234.15
-
Shlay JC, Visnegarwala F, Bartsch G, et al. Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivu-dine. J Acquir Immune Defic Syndr. 2005 ; 38: 147-155. (Pubitemid 40189321)
-
(2005)
Journal of Acquired Immune Deficiency Syndromes
, vol.38
, Issue.2
, pp. 147-155
-
-
Shlay, J.C.1
Visnegarwala, F.2
Bartsch, G.3
Wang, J.4
Peng, G.5
El-Sadr, W.M.6
Gibert, C.7
Kotler, D.8
Grunfeld, C.9
Raghavan, S.10
-
4
-
-
13844255117
-
Impact of dyslipidemia associated with highly active antiretroviral therapy (HAART) on cardiovascular risk and life expectancy
-
DOI 10.1016/j.amjcard.2004.11.004
-
Grover SA, Coupal L, Gilmore N, Mukherjee J. Impact of dyslipidemia associated with highly active antiretroviral therapy (HAART) on cardiovascular risk and life expectancy. Am J Cardiol. 2005 ; 95: 586-591. (Pubitemid 40255245)
-
(2005)
American Journal of Cardiology
, vol.95
, Issue.5
, pp. 586-591
-
-
Grover, S.A.1
Coupal, L.2
Gilmore, N.3
Mukherjee, J.4
-
5
-
-
0034934844
-
Dyslipidaemia in HIV-infected patients: Association with adherence to potent antiretroviral therapy
-
DOI 10.1258/0956462011923507
-
Vergis EN, Paterson DL, Wagener MM, Swindells S, Singh N. Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy. Int J STD AIDS. 2001 ; 12: 463-468. (Pubitemid 32656057)
-
(2001)
International Journal of STD and AIDS
, vol.12
, Issue.7
, pp. 463-468
-
-
Vergis, E.N.1
Paterson, D.L.2
Wagener, M.M.3
Swindells, S.4
Singh, N.5
-
6
-
-
0345151837
-
Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors
-
Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation. 1999 ; 100: 700-705. (Pubitemid 29383638)
-
(1999)
Circulation
, vol.100
, Issue.7
, pp. 700-705
-
-
Periard, D.1
Telenti, A.2
Sudre, P.3
Cheseaux, J.-J.4
Halfon, P.5
Reymond, M.J.6
Marcovina, S.M.7
Glauser, M.P.8
Nicod, P.9
Darioli, R.10
Mooser, V.11
-
7
-
-
20144366551
-
Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV-infected patients: A retrospective cohort study
-
DOI 10.1111/j.1468-1293.2005.00269.x
-
Richter A, Pladevall M, Manjunath R, et al. Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV-infected patients: a retrospective cohort study. HIV Med. 2005 ; 6: 79-90. (Pubitemid 40425971)
-
(2005)
HIV Medicine
, vol.6
, Issue.2
, pp. 79-90
-
-
Richter, A.1
Pladevall, M.2
Manjunath, R.3
Lafata, J.E.4
Xi, H.5
Simpkins, J.6
Brar, I.7
Markowitz, N.8
Iloeje, U.H.9
Irish, W.10
-
8
-
-
12144286934
-
Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles?
-
DOI 10.1086/381783
-
Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles ? J Infect Dis. 2004 ; 189: 1056-1074. (Pubitemid 38373099)
-
(2004)
Journal of Infectious Diseases
, vol.189
, Issue.6
, pp. 1056-1074
-
-
Fontas, E.1
Van Leth, F.2
Sabin, C.A.3
Friis-Moller, N.4
Rickenbach, M.5
D'Arminio Monforte, A.6
Kirk, O.7
Dupon, M.8
Morfeldt, L.9
Mateu, S.10
Petoumenos, K.11
El-Sadr, W.12
De Wit, S.13
Lundgren, J.D.14
Pradier, C.15
Reiss, P.16
-
9
-
-
0037111631
-
Lipodystrophy in a cohort of human immunodeficiency virus-infected asian patients: Prevalence, associated factors, and psychological impact
-
DOI 10.1086/344055
-
Paton NI, Earnest A, Ng YM, Karim F, Aboulhab J. Lipodystrophy in a cohort of human immunodeficiency virus-infected Asian patients: prevalence, associated factors, and psychological impact. Clin Infect Dis. 2002 ; 35: 1244-1249. (Pubitemid 35305873)
-
(2002)
Clinical Infectious Diseases
, vol.35
, Issue.10
, pp. 1244-1249
-
-
Paton, N.I.1
Earnest, A.2
Ng, Y.M.3
Karim, F.4
Aboulhab, J.5
-
11
-
-
15744378534
-
HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting
-
Duncombe C, Kerr SJ, Ruxrungtham K, et al. HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting. AIDS. 2005 ; 19: 169-178. (Pubitemid 40409535)
-
(2005)
AIDS
, vol.19
, Issue.2
, pp. 169-178
-
-
Duncombe, C.1
Kerr, S.J.2
Ruxrungtham, K.3
Dore, G.J.4
Law, M.G.5
Emery, S.6
Lange, J.M.7
Phanuphak, P.8
Cooper, D.A.9
-
12
-
-
3142729178
-
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
-
DOI 10.1161/01.CIR.0000133317.49796.0E
-
Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004 ; 110: 227-239. (Pubitemid 38924592)
-
(2004)
Circulation
, vol.110
, Issue.2
, pp. 227-239
-
-
Grundy, S.M.1
Cleeman, J.I.2
Bairey Merz, C.N.3
Brewer Jr., H.B.4
Clark, L.T.5
Hunninghake, D.B.6
Pasternak, R.C.7
Smith Jr., S.C.8
Stone, N.J.9
-
13
-
-
0035897696
-
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
-
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 ; 285: 2486-2497.
-
(2001)
JAMA
, vol.285
, pp. 2486-2497
-
-
-
14
-
-
34548307594
-
-
DAIDS. Bethesda, Md. Division of Acquired Immunodeficiency Syndrome, National Institute of Allergy and Infectious Diseases, National Institutes of Health;
-
DAIDS. Division of AIDS Table For Grading the Severity of Adult and Pediatric Adverse Events. Bethesda, Md. Division of Acquired Immunodeficiency Syndrome, National Institute of Allergy and Infectious Diseases, National Institutes of Health ; 2004.
-
(2004)
Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events
-
-
-
15
-
-
0041524901
-
Indinavir did not further increase mean triglyceride levels in HIV-infected patients treated with nucleoside reverse transcriptase inhibitors: An analysis of three randomized clinical trials
-
DOI 10.1002/pds.808
-
Rojas C, Coplan PM, Rhodes T, Robertson MN, DiNubile MJ, Guess HA. Indinavir did not further increase mean triglyceride levels in HIV-infected patients treated with nucleoside reverse transcriptase inhibitors: an analysis of three randomized clinical trials. Pharmacoepidemiol Drug Saf. 2003 ; 12: 361-369. (Pubitemid 36903370)
-
(2003)
Pharmacoepidemiology and Drug Safety
, vol.12
, Issue.5
, pp. 361-369
-
-
Rojas, C.1
Coplan, P.M.2
Rhodes, T.3
Robertson, M.N.4
DiNubile, M.J.5
Guess, H.A.6
-
16
-
-
0035461510
-
Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration
-
Buss N, Snell P, Bock J, Hsu A, Jorga K. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br J Clin Pharmacol. 2001 ; 52: 255-264. (Pubitemid 33796222)
-
(2001)
British Journal of Clinical Pharmacology, Supplement
, vol.52
, Issue.3
, pp. 255-264
-
-
Buss, N.1
Snell, P.2
Bock, J.3
Hsu, A.4
Jorga, K.5
-
17
-
-
2042445714
-
Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients
-
DOI 10.1097/00002030-200403260-00017
-
Negredo E, Ribalta J, Ferre R, et al. Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients. AIDS. 2004 ; 18: 819-821. (Pubitemid 38535014)
-
(2004)
AIDS
, vol.18
, Issue.5
, pp. 819-821
-
-
Negredo, E.1
Ribalta, J.2
Ferre, R.3
Salazar, J.4
Rey-Joly, C.5
Sirera, G.6
Masana, L.7
Clotet, B.8
-
18
-
-
15744367156
-
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1
-
van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 2004 ; 1: e19 - e19.
-
(2004)
PLoS Med
, vol.1
-
-
Van Leth, F.1
Phanuphak, P.2
Stroes, E.3
-
19
-
-
0037093813
-
Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy
-
DOI 10.1086/339866
-
Saves M, Raffi F, Capeau J, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immuno-deficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2002 ; 34: 1396-1405. (Pubitemid 34507951)
-
(2002)
Clinical Infectious Diseases
, vol.34
, Issue.10
, pp. 1396-1405
-
-
Saves, M.1
Raffi, F.2
Capeau, J.3
Rozenbaum, W.4
Ragnaud, J.-M.5
Perronne, C.6
Basdevant, A.7
Leport, C.8
Chene, G.9
Salamon, R.10
Brun-Vezinet, F.11
Fleury, H.12
Peytavin, G.13
Moatti, J.-P.14
Pierret, J.15
Costagliola, D.16
Dellamonica, P.17
Katlama, C.18
Meyer, L.19
Morin, M.20
Sicard, D.21
Sobel, A.22
Vincent-Ballereau, F.23
Dupon, M.24
Le Moing, V.25
Marchou, B.26
May, T.27
Morlat, P.28
Waldner-Combernoux, A.29
Bard, J.-M.30
Coussieu, C.31
Gharakhanian, S.32
Krempf, M.33
Alfaro, C.34
Barennes, C.35
Cailleton, V.36
Carrieri, M.P.37
Deveaud, C.38
Droz, C.39
Dupouy, G.40
Duran, S.41
Dutoit, S.42
Ecobichon, J.L.43
Egouy, C.44
Germain, C.45
Jadand, C.46
Journot, V.47
Lassalle, R.48
Latour, L.49
Lawson-Ayayi, S.50
Le Moing, V.51
Lewden, C.52
Masquelier, B.53
Nouioua, W.54
Palmer, G.55
Pereira, E.56
Roloff, S.57
Ronde-Ousteau, V.58
Sangue, A.59
Souville, M.60
Spire, B.61
Surzyn, J.62
Winum, R.63
Chennebault, J.-M.64
Faller, J.-P.65
Estavoyer, J.M.66
Laurent, R.67
Vuitton, D.68
Beylot, J.69
Lacut, J.-Y.70
Le Bras, M.71
Ragnaud, J.-M.72
Granier, P.73
Garre, M.74
Bazin, C.75
Veyssier, P.76
Devidas, A.77
Sobel, A.78
Perronne, C.79
Lagarde, P.80
Ceccaldi, J.81
Peyramond, D.82
Allard, C.83
Reynes, J.84
Canton, P.85
Cassuto, J.-P.86
Arsac, P.87
Bricaire, F.88
Caulin, C.89
Frottier, J.90
Herson, S.91
Imbert, J.-C.92
Malkin, J.-E.93
Vachon, F.94
Vilde, J.-L.95
Becq-Giraudon, B.96
Remy, G.97
Cartier, F.98
Roue, R.99
more..
-
20
-
-
28444436183
-
Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009
-
DOI 10.1111/j.1468-1293.2005.00327.x
-
Boyd MA, Siangphoe U, Ruxrungtham K, et al. Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination NRTIs: 96-week outcomes of HIV-NAT 009. HIV Med. 2005 ; 6: 410-420. (Pubitemid 41723309)
-
(2005)
HIV Medicine
, vol.6
, Issue.6
, pp. 410-420
-
-
Boyd, M.A.1
Siangphoe, U.2
Ruxrungtham, K.3
Duncombe, C.J.4
Stek, M.5
Lange, J.M.A.6
Cooper, D.A.7
Phanuphak, P.8
-
21
-
-
0141612910
-
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: The MaxCmin1 trial
-
DOI 10.1086/377288
-
Dragsted UB, Gerstoft J, Pedersen C, et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis. 2003 ; 188: 635-642. (Pubitemid 37115175)
-
(2003)
Journal of Infectious Diseases
, vol.188
, Issue.5
, pp. 635-642
-
-
Dragsted, U.B.1
Gerstoft, J.2
Pedersen, C.3
Peters, B.4
Duran, A.5
Obel, N.6
Castagna, A.7
Cahn, P.8
Clumeck, N.9
Bruun, J.N.10
Benetucci, J.11
Hill, A.12
Cassetti, I.13
Vernazza, P.14
Youle, M.15
Fox, Z.16
Lundgren, J.D.17
-
22
-
-
0042832397
-
Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group
-
DOI 10.1086/378131
-
Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003 ; 37: 613-627. (Pubitemid 37100800)
-
(2003)
Clinical Infectious Diseases
, vol.37
, Issue.5
, pp. 613-627
-
-
Dube, M.P.1
Stein, J.H.2
Aberg, J.A.3
Fichtenbaum, C.J.4
Gerber, J.G.5
Tashima, K.T.6
Henry, W.K.7
Currier, J.S.8
Sprecher, D.9
Glesby, M.J.10
-
23
-
-
28344452695
-
Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients
-
DOI 10.1016/j.atherosclerosis.2005.04.013, PII S0021915005002959
-
Asztalos BF, Schaefer EJ, Horvath KV, et al. Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients. Atherosclerosis. 2006 ; 184: 72-77. (Pubitemid 41721071)
-
(2006)
Atherosclerosis
, vol.184
, Issue.1
, pp. 72-77
-
-
Asztalos, B.F.1
Schaefer, E.J.2
Horvath, K.V.3
Cox, C.E.4
Skinner, S.5
Gerrior, J.6
Gorbach, S.L.7
Wanke, C.8
-
26
-
-
19644395095
-
Lipodystrophy and dyslipidemia among patients taking first-line, world health organization-recommended highly active antiretroviral therapy regimens in Western India
-
Pujari SN, Dravid A, Naik E, et al. Lipodystrophy and dyslipidemia among patients taking first-line, world health organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr. 2005 ; 39: 199-202. (Pubitemid 40741119)
-
(2005)
Journal of Acquired Immune Deficiency Syndromes
, vol.39
, Issue.2
, pp. 199-202
-
-
Pujari, S.N.1
Dravid, A.2
Naik, E.3
Bhagat, S.4
Tash, K.5
Nadler, J.P.6
Sinnott, J.T.7
-
27
-
-
3042848853
-
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial
-
DOI 10.1001/jama.292.2.191
-
Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004 ; 292: 191-201. (Pubitemid 38917996)
-
(2004)
Journal of the American Medical Association
, vol.292
, Issue.2
, pp. 191-201
-
-
Gallant, J.E.1
Staszewski, S.2
Pozniak, A.L.3
DeJesus, E.4
Suleiman, J.M.A.H.5
Miller, M.D.6
Coakley, D.F.7
Lu, B.8
Toole, J.J.9
Cheng, A.K.10
|